Metformin
Antidiabetic biguanide; activates AMPK (ZHO2001) and inhibits mTORC1. How much of its action actually runs through AMPK is disputed: metformin still suppresses hepatic gluconeogenesis in AMPK-null and LKB1-null mouse liver (FOR2010) and still inhibits mTORC1 in AMPK-null cells, via the Rag GTPases (KAL2010). Frequently discussed as a geroprotector alongside rapamycin.
A diabetes drug that quietens mTORC1 indirectly. A widely used diabetes drug that switches on AMPK and, through that, dials down mTORC1. Exactly how much of its effect runs through AMPK versus other routes is still debated - it still works in cells that lack AMPK entirely. It's often discussed as a possible longevity drug alongside rapamycin.
Complex I inhibition→AMPK, AMPK-independent Rag inhibition, lysosomal PEN2–ATP6AP1 sensing and gut-microbiome effects have all been proposed; clinical doses may not reach the concentrations used in vitro.
TL;DR. Metformin appears in 9 curated studies in Oliver's mTOR Atlas: 1 in people (1 human study); 2 in animal models; 6 at the molecular level (cells, biochemistry, structure). It has 2 interactions in the curated pathway model.
In the pathway model
| Interaction | Mechanism | Evidence | Studies |
|---|---|---|---|
| Metformin activates AMPK mechanism: signal-relay · this link in full · on the map table | Metformin shifts the cell's energy balance and switches AMPK on – its best-known route to affecting this pathway. Holds under: How much of metformin's effect actually runs through AMPK is disputed: it still suppresses hepatic gluconeogenesis in AMPK-null and LKB1-null mouse liver (FOR2010) and still inhibits mTORC1 in AMPK-null cells (KAL2010). See the parallel METFORMIN-MTORC1 edge. plausible in people, not shown directly · disputed: at least one study points the other way | A | ZHO2001, PEA2009 conflicting: KAL2010 |
| Metformin inhibits mTORC1 mechanism: signal-relay · this link in full · on the map table | Metformin can also block mTORC1 through a separate route that doesn't need AMPK – a route often left out of the simple "metformin works via AMPK" story. This was shown in cells and mice, often at doses higher than patients take, and how much each route matters in people is not known. Holds under: Runs in parallel with METFORMIN-AMPK, not instead of it. The relative weight of the two routes in humans is unresolved. Dose is the whole argument. Concentrations used in cell culture are typically far above plasma levels achieved at clinical doses, so in vitro mechanism may not describe what metformin does in a patient. plausible in people, not shown directly · disputed: at least one study points the other way | M | KAL2010 |
Evidence at a glance
| Evidence | What it means | Studies |
|---|---|---|
| H | Human study | 1 |
| A | Animal model | 2 |
| M | Molecular — cells, biochemistry, structure | 6 |
Studies
| Year | Evidence | Study |
|---|---|---|
| 2014 | H | Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls BAN2014 Diabetic patients started on metformin had longer median survival than matched non-diabetic controls without the drug. Retrospective and observational: consistent with a survival benefit, but confounding by indication and healthy-adherer effects cannot be excluded. |
| 2010 | A | Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state FOR2010 The paper that broke the simple 'metformin works through AMPK' story. Metformin still suppressed hepatic glucose production in mice and hepatocytes lacking AMPK or LKB1, acting instead through a fall in hepatic energy charge. Any claim that metformin's benefit is AMPK-mediated has to answer this result. |
| 2009 | A | Enhancing CD8 T-cell memory by modulating fatty acid metabolism PEA2009 Mice whose T cells lacked the adaptor protein TRAF6 mounted a normal effector CD8 T-cell response to Listeria infection, but the antigen-specific cells vanished during contraction and almost no memory cells formed. The TRAF6-deficient cells failed to activate AMPK and mitochondrial fatty acid oxidation when the growth factor IL-2 was withdrawn. Daily metformin restored fatty acid oxidation and memory formation, and also raised memory CD8 T-cell numbers in normal mice: in a tumour vaccine model 6 of 9 metformin-treated mice survived beyond day 33 against 1 of 8 controls. Daily rapamycin (1.5 mg/kg), used as a second drug that promotes fatty acid oxidation, likewise increased memory CD8 T-cell development and recall responses. Boundary: mouse only, one bacterial infection model and one transplantable tumour; the rapamycin arm is a secondary experiment and mTOR activity itself was not measured in these cells. |
| 2026 | M | A Systems Pharmacology Model of Aging Identifies Optimal Combination Therapies With Secondary Benefits on Weight Loss and Metabolic Health GOR2026 A calibrated systems-pharmacology model of aging finds that optimal drug combinations diverge by objective: GLP-1 receptor agonist + SGLT2 inhibitor + metformin is best for metabolic (weight/HbA1c) improvement, while GLP-1 receptor agonist + SGLT2 inhibitor + rapamycin is predicted best for aging-related (frailty/biological-age-gap) benefit — the two goals do not converge on the same regimen. Authors flag the aging predictions as hypothesis-generating, pending external validation. |
| 2017 | M | Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex HOW2017 Pinned down HOW the diabetes drug metformin - a major longevity candidate - actually reaches mTOR. In the liver, metformin lowers cellular energy, and at low doses this shuts down mTORC1 specifically through AMPK and the TSC complex. Direct mechanistic bridge between a widely-used drug, energy sensing, and the mTOR pathway. |
| 2012 | M | Distinct perturbation of the translatome by the antidiabetic drug metformin LAR2012 The authors compared genome-wide changes in mRNA translation caused by metformin with those caused by the mTOR inhibitors rapamycin and PP242 in cancer cells. Metformin changed gene expression at the level of translation to an extent comparable to the classic mTOR inhibitors. Its antiproliferative effect could be explained by selective suppression of translation of mRNAs encoding cell-cycle regulators, acting through the mTORC1 / 4E-BP pathway. The paper provided evidence that metformin's effect on cell growth in vitro goes through selective translational control rather than a general drop in protein synthesis. Boundary: Cultured cancer cells at drug concentrations used in vitro; does not show that metformin at clinical doses acts this way in patients. Drafted from the abstract only. |
| 2011 | M | Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets MIC2011 Comparing CD4 T cells grown under effector and regulatory conditions, the authors showed that Th1, Th2 and Th17 cells carry high surface Glut1 and are strongly glycolytic, while inducible Treg carry little Glut1, oxidise lipid at a higher rate and have more phosphorylated AMPK. Blocking lipid oxidation with etomoxir selectively suppressed Treg generation and left effector differentiation intact, whereas removing glucose blocked Th17 but not Treg. Both rapamycin and metformin raised fatty acid oxidation in stimulated CD4 T cells, and etomoxir prevented the Treg increase produced by rapamycin or TGF-beta, which ties the pro-Treg effect of mTOR inhibition to lipid oxidation. In a mouse asthma model, metformin lowered Glut1 on activated CD4 T cells and increased the proportion and number of Treg in draining lymph nodes, although airway responsiveness itself did not change significantly. Boundary: mouse cells and one mouse allergic-airway model; mTOR inhibition is pharmacological (rapamycin) and mTOR activity was not measured directly, so the mTOR arm is inferred from drug effects. |
| 2010 | M | Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner KAL2010 Metformin inhibits mTORC1 even in cells lacking AMPK or TSC1/TSC2, and the effect requires the Rag GTPases instead. Together with Foretz 2010 this places a large part of metformin's action outside the AMPK axis it is usually credited to. |
| 2001 | M | Role of AMP-activated protein kinase in mechanism of metformin action ZHO2001 Metformin activates AMPK, suppressing hepatic gluconeogenesis and lipogenesis. |
Related entities
Was this page useful?
Thank you. Your answer was counted anonymously.